Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma

Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People’s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had >12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (>12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (>12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P<0.001; cancer-specific, P<0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P<0.001) and cancer-specific survival (P<0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703–0.777, P<0.001; cancer-specific, HR=0.742, 95% CI=0.698–0.788, P<0.001) and multivariate (overall, HR=0.601, 95% CI=0.537–0.673, P<0.001; cancer-specific, HR=0.582, 95% CI=0.511–0.664, P<0.001) Cox proportional hazards models verified the association between >12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes >12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ma Y [verfasserIn] Luo YQ [verfasserIn] Lin N [verfasserIn] Lv YZ [verfasserIn] Zhou Y [verfasserIn] Li B [verfasserIn] Han KN [verfasserIn] Jiang S [verfasserIn] Gao JJ [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2018

Schlagwörter:	Number of lymph node examined stages mucinous carcinoma

Übergeordnetes Werk:	In: OncoTargets and Therapy - Dove Medical Press, 2009, (2018), Seite 3659-3670
Übergeordnetes Werk:	year:2018 ; pages:3659-3670

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ011901357

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ011901357
003	DE-627
005	20230310040917.0
007	cr uuu---uuuuu
008	230225s2018 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ011901357
035			\|a (DE-599)DOAJea9b4e5a9faa4adbb8f8b44597c1c5a4
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC254-282
100	0		\|a Ma Y \|e verfasserin \|4 aut
245	1	0	\|a Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma
264		1	\|c 2018
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People’s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had >12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (>12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (>12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P<0.001; cancer-specific, P<0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P<0.001) and cancer-specific survival (P<0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703–0.777, P<0.001; cancer-specific, HR=0.742, 95% CI=0.698–0.788, P<0.001) and multivariate (overall, HR=0.601, 95% CI=0.537–0.673, P<0.001; cancer-specific, HR=0.582, 95% CI=0.511–0.664, P<0.001) Cox proportional hazards models verified the association between >12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes >12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma
650		4	\|a Number of lymph node examined
650		4	\|a stages
650		4	\|a mucinous carcinoma
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Luo YQ \|e verfasserin \|4 aut
700	0		\|a Lin N \|e verfasserin \|4 aut
700	0		\|a Lv YZ \|e verfasserin \|4 aut
700	0		\|a Zhou Y \|e verfasserin \|4 aut
700	0		\|a Li B \|e verfasserin \|4 aut
700	0		\|a Han KN \|e verfasserin \|4 aut
700	0		\|a Jiang S \|e verfasserin \|4 aut
700	0		\|a Gao JJ \|e verfasserin \|4 aut
773	0	8	\|i In \|t OncoTargets and Therapy \|d Dove Medical Press, 2009 \|g (2018), Seite 3659-3670 \|w (DE-627)600307654 \|w (DE-600)2495130-4 \|x 11786930 \|7 nnns
773	1	8	\|g year:2018 \|g pages:3659-3670
856	4	0	\|u https://doaj.org/article/ea9b4e5a9faa4adbb8f8b44597c1c5a4 \|z kostenfrei
856	4	0	\|u https://www.dovepress.com/prognostic-impact-of-the-number-of-lymph-nodes-examined-in-different-s-peer-reviewed-article-OTT \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1178-6930 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2018 \|h 3659-3670

Indexfelder

author_variant	m y my l y ly l n ln l y ly z y zy l b lb h k hk j s js g j gj
matchkey_str	article:11786930:2018----::rgotcmatfhnmeolmhoeeaieidfeettgsfooe
hierarchy_sort_str	2018
callnumber-subject-code	RC
publishDate	2018
allfields	(DE-627)DOAJ011901357 (DE-599)DOAJea9b4e5a9faa4adbb8f8b44597c1c5a4 DE-627 ger DE-627 rakwb eng RC254-282 Ma Y verfasserin aut Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People’s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had >12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (>12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (>12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P<0.001; cancer-specific, P<0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P<0.001) and cancer-specific survival (P<0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703–0.777, P<0.001; cancer-specific, HR=0.742, 95% CI=0.698–0.788, P<0.001) and multivariate (overall, HR=0.601, 95% CI=0.537–0.673, P<0.001; cancer-specific, HR=0.582, 95% CI=0.511–0.664, P<0.001) Cox proportional hazards models verified the association between >12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes >12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma Number of lymph node examined stages mucinous carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens Luo YQ verfasserin aut Lin N verfasserin aut Lv YZ verfasserin aut Zhou Y verfasserin aut Li B verfasserin aut Han KN verfasserin aut Jiang S verfasserin aut Gao JJ verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2018), Seite 3659-3670 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2018 pages:3659-3670 https://doaj.org/article/ea9b4e5a9faa4adbb8f8b44597c1c5a4 kostenfrei https://www.dovepress.com/prognostic-impact-of-the-number-of-lymph-nodes-examined-in-different-s-peer-reviewed-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2018 3659-3670
spelling	(DE-627)DOAJ011901357 (DE-599)DOAJea9b4e5a9faa4adbb8f8b44597c1c5a4 DE-627 ger DE-627 rakwb eng RC254-282 Ma Y verfasserin aut Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People’s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had >12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (>12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (>12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P<0.001; cancer-specific, P<0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P<0.001) and cancer-specific survival (P<0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703–0.777, P<0.001; cancer-specific, HR=0.742, 95% CI=0.698–0.788, P<0.001) and multivariate (overall, HR=0.601, 95% CI=0.537–0.673, P<0.001; cancer-specific, HR=0.582, 95% CI=0.511–0.664, P<0.001) Cox proportional hazards models verified the association between >12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes >12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma Number of lymph node examined stages mucinous carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens Luo YQ verfasserin aut Lin N verfasserin aut Lv YZ verfasserin aut Zhou Y verfasserin aut Li B verfasserin aut Han KN verfasserin aut Jiang S verfasserin aut Gao JJ verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2018), Seite 3659-3670 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2018 pages:3659-3670 https://doaj.org/article/ea9b4e5a9faa4adbb8f8b44597c1c5a4 kostenfrei https://www.dovepress.com/prognostic-impact-of-the-number-of-lymph-nodes-examined-in-different-s-peer-reviewed-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2018 3659-3670
allfields_unstemmed	(DE-627)DOAJ011901357 (DE-599)DOAJea9b4e5a9faa4adbb8f8b44597c1c5a4 DE-627 ger DE-627 rakwb eng RC254-282 Ma Y verfasserin aut Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People’s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had >12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (>12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (>12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P<0.001; cancer-specific, P<0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P<0.001) and cancer-specific survival (P<0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703–0.777, P<0.001; cancer-specific, HR=0.742, 95% CI=0.698–0.788, P<0.001) and multivariate (overall, HR=0.601, 95% CI=0.537–0.673, P<0.001; cancer-specific, HR=0.582, 95% CI=0.511–0.664, P<0.001) Cox proportional hazards models verified the association between >12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes >12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma Number of lymph node examined stages mucinous carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens Luo YQ verfasserin aut Lin N verfasserin aut Lv YZ verfasserin aut Zhou Y verfasserin aut Li B verfasserin aut Han KN verfasserin aut Jiang S verfasserin aut Gao JJ verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2018), Seite 3659-3670 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2018 pages:3659-3670 https://doaj.org/article/ea9b4e5a9faa4adbb8f8b44597c1c5a4 kostenfrei https://www.dovepress.com/prognostic-impact-of-the-number-of-lymph-nodes-examined-in-different-s-peer-reviewed-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2018 3659-3670
allfieldsGer	(DE-627)DOAJ011901357 (DE-599)DOAJea9b4e5a9faa4adbb8f8b44597c1c5a4 DE-627 ger DE-627 rakwb eng RC254-282 Ma Y verfasserin aut Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People’s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had >12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (>12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (>12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P<0.001; cancer-specific, P<0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P<0.001) and cancer-specific survival (P<0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703–0.777, P<0.001; cancer-specific, HR=0.742, 95% CI=0.698–0.788, P<0.001) and multivariate (overall, HR=0.601, 95% CI=0.537–0.673, P<0.001; cancer-specific, HR=0.582, 95% CI=0.511–0.664, P<0.001) Cox proportional hazards models verified the association between >12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes >12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma Number of lymph node examined stages mucinous carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens Luo YQ verfasserin aut Lin N verfasserin aut Lv YZ verfasserin aut Zhou Y verfasserin aut Li B verfasserin aut Han KN verfasserin aut Jiang S verfasserin aut Gao JJ verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2018), Seite 3659-3670 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2018 pages:3659-3670 https://doaj.org/article/ea9b4e5a9faa4adbb8f8b44597c1c5a4 kostenfrei https://www.dovepress.com/prognostic-impact-of-the-number-of-lymph-nodes-examined-in-different-s-peer-reviewed-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2018 3659-3670
allfieldsSound	(DE-627)DOAJ011901357 (DE-599)DOAJea9b4e5a9faa4adbb8f8b44597c1c5a4 DE-627 ger DE-627 rakwb eng RC254-282 Ma Y verfasserin aut Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People’s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had >12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (>12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (>12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P<0.001; cancer-specific, P<0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P<0.001) and cancer-specific survival (P<0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703–0.777, P<0.001; cancer-specific, HR=0.742, 95% CI=0.698–0.788, P<0.001) and multivariate (overall, HR=0.601, 95% CI=0.537–0.673, P<0.001; cancer-specific, HR=0.582, 95% CI=0.511–0.664, P<0.001) Cox proportional hazards models verified the association between >12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes >12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma Number of lymph node examined stages mucinous carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens Luo YQ verfasserin aut Lin N verfasserin aut Lv YZ verfasserin aut Zhou Y verfasserin aut Li B verfasserin aut Han KN verfasserin aut Jiang S verfasserin aut Gao JJ verfasserin aut In OncoTargets and Therapy Dove Medical Press, 2009 (2018), Seite 3659-3670 (DE-627)600307654 (DE-600)2495130-4 11786930 nnns year:2018 pages:3659-3670 https://doaj.org/article/ea9b4e5a9faa4adbb8f8b44597c1c5a4 kostenfrei https://www.dovepress.com/prognostic-impact-of-the-number-of-lymph-nodes-examined-in-different-s-peer-reviewed-article-OTT kostenfrei https://doaj.org/toc/1178-6930 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2018 3659-3670
language	English
source	In OncoTargets and Therapy (2018), Seite 3659-3670 year:2018 pages:3659-3670
sourceStr	In OncoTargets and Therapy (2018), Seite 3659-3670 year:2018 pages:3659-3670
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Number of lymph node examined stages mucinous carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	OncoTargets and Therapy
authorswithroles_txt_mv	Ma Y @@aut@@ Luo YQ @@aut@@ Lin N @@aut@@ Lv YZ @@aut@@ Zhou Y @@aut@@ Li B @@aut@@ Han KN @@aut@@ Jiang S @@aut@@ Gao JJ @@aut@@
publishDateDaySort_date	2018-01-01T00:00:00Z
hierarchy_top_id	600307654
id	DOAJ011901357
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ011901357</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310040917.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ011901357</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJea9b4e5a9faa4adbb8f8b44597c1c5a4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ma Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People&rsquo;s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had &gt;12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (&gt;12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (&gt;12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P&lt;0.001; cancer-specific, P&lt;0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P&lt;0.001) and cancer-specific survival (P&lt;0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703&ndash;0.777, P&lt;0.001; cancer-specific, HR=0.742, 95% CI=0.698&ndash;0.788, P&lt;0.001) and multivariate (overall, HR=0.601, 95% CI=0.537&ndash;0.673, P&lt;0.001; cancer-specific, HR=0.582, 95% CI=0.511&ndash;0.664, P&lt;0.001) Cox proportional hazards models verified the association between &gt;12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes &gt;12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Number of lymph node examined</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">stages</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mucinous carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luo YQ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lin N</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lv YZ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhou Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Li B</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Han KN</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jiang S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gao JJ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">OncoTargets and Therapy</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2018), Seite 3659-3670</subfield><subfield code="w">(DE-627)600307654</subfield><subfield code="w">(DE-600)2495130-4</subfield><subfield code="x">11786930</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2018</subfield><subfield code="g">pages:3659-3670</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ea9b4e5a9faa4adbb8f8b44597c1c5a4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/prognostic-impact-of-the-number-of-lymph-nodes-examined-in-different-s-peer-reviewed-article-OTT</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-6930</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2018</subfield><subfield code="h">3659-3670</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Ma Y
spellingShingle	Ma Y misc RC254-282 misc Number of lymph node examined misc stages misc mucinous carcinoma misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma
authorStr	Ma Y
ppnlink_with_tag_str_mv	@@773@@(DE-627)600307654
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC254-282
illustrated	Not Illustrated
issn	11786930
topic_title	RC254-282 Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma Number of lymph node examined stages mucinous carcinoma
topic	misc RC254-282 misc Number of lymph node examined misc stages misc mucinous carcinoma misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc RC254-282 misc Number of lymph node examined misc stages misc mucinous carcinoma misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc RC254-282 misc Number of lymph node examined misc stages misc mucinous carcinoma misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	OncoTargets and Therapy
hierarchy_parent_id	600307654
hierarchy_top_title	OncoTargets and Therapy
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)600307654 (DE-600)2495130-4
title	Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma
ctrlnum	(DE-627)DOAJ011901357 (DE-599)DOAJea9b4e5a9faa4adbb8f8b44597c1c5a4
title_full	Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma
author_sort	Ma Y
journal	OncoTargets and Therapy
journalStr	OncoTargets and Therapy
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2018
contenttype_str_mv	txt
container_start_page	3659
author_browse	Ma Y Luo YQ Lin N Lv YZ Zhou Y Li B Han KN Jiang S Gao JJ
class	RC254-282
format_se	Elektronische Aufsätze
author-letter	Ma Y
author2-role	verfasserin
title_sort	prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma
callnumber	RC254-282
title_auth	Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma
abstract	Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People’s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had >12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (>12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (>12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P<0.001; cancer-specific, P<0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P<0.001) and cancer-specific survival (P<0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703–0.777, P<0.001; cancer-specific, HR=0.742, 95% CI=0.698–0.788, P<0.001) and multivariate (overall, HR=0.601, 95% CI=0.537–0.673, P<0.001; cancer-specific, HR=0.582, 95% CI=0.511–0.664, P<0.001) Cox proportional hazards models verified the association between >12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes >12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma
abstractGer	Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People’s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had >12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (>12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (>12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P<0.001; cancer-specific, P<0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P<0.001) and cancer-specific survival (P<0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703–0.777, P<0.001; cancer-specific, HR=0.742, 95% CI=0.698–0.788, P<0.001) and multivariate (overall, HR=0.601, 95% CI=0.537–0.673, P<0.001; cancer-specific, HR=0.582, 95% CI=0.511–0.664, P<0.001) Cox proportional hazards models verified the association between >12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes >12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma
abstract_unstemmed	Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People’s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had >12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (>12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (>12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P<0.001; cancer-specific, P<0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P<0.001) and cancer-specific survival (P<0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703–0.777, P<0.001; cancer-specific, HR=0.742, 95% CI=0.698–0.788, P<0.001) and multivariate (overall, HR=0.601, 95% CI=0.537–0.673, P<0.001; cancer-specific, HR=0.582, 95% CI=0.511–0.664, P<0.001) Cox proportional hazards models verified the association between >12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes >12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
title_short	Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma
url	https://doaj.org/article/ea9b4e5a9faa4adbb8f8b44597c1c5a4 https://www.dovepress.com/prognostic-impact-of-the-number-of-lymph-nodes-examined-in-different-s-peer-reviewed-article-OTT https://doaj.org/toc/1178-6930
remote_bool	true
author2	Luo YQ Lin N Lv YZ Zhou Y Li B Han KN Jiang S Gao JJ
author2Str	Luo YQ Lin N Lv YZ Zhou Y Li B Han KN Jiang S Gao JJ
ppnlink	600307654
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC254-282
up_date	2024-07-03T22:47:52.974Z
_version_	1803599869880827905
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ011901357</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230310040917.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2018 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ011901357</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJea9b4e5a9faa4adbb8f8b44597c1c5a4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ma Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Yong Ma,* Yiqian Luo,* Nan Lin, Yongzhu Lv, Yang Zhou, Bing Li, Kunna Han, Song Jiang, Jianjun Gao Department of General Surgery, 210 Hospital of Chinese People&rsquo;s Liberation Army, Dalian 116000, Liaoning, China *These authors contributed equally to this work Background: Mucinous adenocarcinoma (MC) is a special kind of colorectal adenocarcinoma that occurs more frequently in young patients and females, but the prognostic effect of lymph nodes in MC patients is unclear. This population-based study was conducted to analyze the prognostic value of the number of lymph nodes examined in different stages of colorectal MC. Methods: We included 17,001 MC patients from the Surveillance, Epidemiology, and End Results program database between 2003 and 2013, of which 12,812 (75%) had &gt;12 lymph nodes examined. Results: Compared to the group with insufficient lymph nodes examined, patients with more lymph nodes (&gt;12) examined tended to come from east and central America, were more frequently female and young, were diagnosed after 2008, had larger-sized tumors of less differentiated grade and in later stages, had not received radiation therapy and had more positive nodal status. Patients with more lymph nodes (&gt;12) examined demonstrated significantly better survival than those with insufficient lymph nodes examined only in stages II and III (stage II: overall, P&lt;0.001; cancer-specific, P&lt;0.001; stage III: overall, P=0.093; cancer-specific, P=0.032), even though the overall (P&lt;0.001) and cancer-specific survival (P&lt;0.001) showed significant differences between the two groups. Both univariate (overall, HR=0.739, 95% CI=0.703&ndash;0.777, P&lt;0.001; cancer-specific, HR=0.742, 95% CI=0.698&ndash;0.788, P&lt;0.001) and multivariate (overall, HR=0.601, 95% CI=0.537&ndash;0.673, P&lt;0.001; cancer-specific, HR=0.582, 95% CI=0.511&ndash;0.664, P&lt;0.001) Cox proportional hazards models verified the association between &gt;12 lymph nodes examined and better survival. Conclusion: More number of lymph nodes &gt;12) examined significantly increased the survival probability of MC patients in stages II and III, but had no significant influence on patients in stages I and IV, indicating the effect of number of lymph nodes examined was a stage-dependent prognostic factor in clinical utility. Keywords: number of lymph nodes examined, stages, mucinous carcinoma</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Number of lymph node examined</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">stages</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">mucinous carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luo YQ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lin N</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Lv YZ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhou Y</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Li B</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Han KN</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jiang S</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Gao JJ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">OncoTargets and Therapy</subfield><subfield code="d">Dove Medical Press, 2009</subfield><subfield code="g">(2018), Seite 3659-3670</subfield><subfield code="w">(DE-627)600307654</subfield><subfield code="w">(DE-600)2495130-4</subfield><subfield code="x">11786930</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2018</subfield><subfield code="g">pages:3659-3670</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ea9b4e5a9faa4adbb8f8b44597c1c5a4</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.dovepress.com/prognostic-impact-of-the-number-of-lymph-nodes-examined-in-different-s-peer-reviewed-article-OTT</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1178-6930</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2018</subfield><subfield code="h">3659-3670</subfield></datafield></record></collection>
score	7.4010954

Nicht das Richtige dabei?

Schreiben Sie uns!

Prognostic impact of the number of lymph nodes examined in different stages of colorectal mucinous adenocarcinoma

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?